This startup produces cannabis-derived veterinary medicine that effectively treats pain in companion animals, offering a safer alternative to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) without the associated side effects. By enhancing animal well-being through targeted food supplements, the company provides pet owners with a reliable solution for managing their pets' pain.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Companion animals experiencing pain are often treated with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which can cause significant side effects. Current veterinary pain management options may not always provide effective relief or may compromise the animal's overall well-being.
Solution
Hale Animal Health is developing novel veterinary pharmaceuticals derived from cannabis to address pain management in companion animals. Their mission is to improve the quality of life for pets by providing safe and effective alternatives to traditional treatments. These products aim to offer relief without the adverse effects commonly associated with NSAIDs, enhancing the overall well-being of pets. Hale Animal Health is focused on creating innovative solutions that meet the specific needs of animals, ensuring both efficacy and safety. They are currently conducting clinical trials to further validate the effectiveness of their formulations.
Target Audience
The primary target audience includes veterinarians and pet owners seeking safer and more effective pain management solutions for their companion animals.
Features
- Cannabis-derived veterinary pharmaceuticals for companion animals
- Formulations designed to minimize side effects compared to NSAIDs
- Products currently under development and undergoing clinical trials
- Targeted solutions for pain management in dogs and cats